日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

US EUROPE AFRICA ASIA 中文
Business / Companies

Global firms could enter hepatitis vaccine market

By Yao Jing (China Daily) Updated: 2014-01-10 14:08

Following the suspension of local suppliers, GSK, J & J may win contracts

Global firms could enter hepatitis vaccine market

British pharmaceutical giant GlaxoSmithKline Plc and Berna Biotech, a division of Johnson & Johnson, are major players in China's hepatitis B vaccine market. Provided to China Daily

Global firms could enter hepatitis vaccine market

Despite Chinese health authorities' claim that there's no link between hepatitis B vaccinations and several babies' deaths, parents' confidence in domestic vaccinations has been shaken - and that's boosting the outlook for overseas drug companies.

Many people "are willing to pay more for the higher quality and safety of imported vaccines", said Guo Wei, an analyst with Ipsos, a global market-research company.

Chinese parents have long opted for domestic vaccines, as the cost of immunizations is mostly covered by the government through the National Immunization Program. But many are now deciding to pay directly for expensive imported vaccines.

Chen Chen, a 27-year-old mother in Hunan province, said that she'll seek more information about overseas vaccine producers and then make a "prudent" decision for her 6-month-old son.

"Overseas vaccine makers are barred from the Class I market, which is supported by the government through the NIP," said Guo.

Some overseas makers, such as Switzerland-based pharmaceutical company Novartis AG, have moved into the market through mergers and acquisitions. But they're limited in terms of local manufacturing.

Low market share

But in the non-NIP Class II market, overseas producers see a potential market. And they can cooperate with the government to serve more consumers who are willing to pay higher fees.

British pharmaceutical giant GlaxoSmithKline Plc and Berna Biotech, a division of Johnson & Johnson, are major players in China's hepatitis B vaccine market.

"But they only participate in the non-NIP Class II market, which costs more and is paid out-of-pocket. Their market shares are estimated to be in the single digits," said Bruce Liu, partner and co-head of the pharmaceutical and health care practice at Roland Berger Strategy Consultants.

The crisis of confidence in domestic vaccines is offering multinationals a rare chance to play an important role both in the Class II market and conceivably in the NIP, such as working with governments, non-governmental organizations and charitable foundations, Liu pointed out.

Liu suggested that MNCs can also consider licensing out new vaccine technology to reputable local partners in exchange for revenue sharing, market access and goodwill.

GSK, which reported a slide in its China pharmaceuticals and vaccines business after the company became embroiled in a series of bribery scandals, may see a rebound.

Ma Yuan, corporate communications manager at GSK China, said it is too early to predict any trend. "But GSK has licensed more vaccines in China than any other global manufacturer," she said.

GSK will continue to invest in the manufacturing, development and commercialization of high-quality, innovative vaccines, the company said.

Hepatitis B vaccines sold in China are mainly produced by seven companies, including GSK. Only two have passed China's new good-manufacturing practice certification, and these two companies have less than 10 percent of the market.

Previous Page 1 2 Next Page

...
...
主站蜘蛛池模板: 国产欧美日韩综合精品一区二区 | 国产精品不卡 | 国产日韩一区二区三免费高清 | 欧美福利 | 电视剧全部免费观看 | 五月天婷婷在线视频 | 久久一精品| 久草久草久草久草 | 91精品国产露脸在线 | 久久综合一 | 日韩中文字幕在线播放 | 一区二区三区在线观看免费 | 日本不卡免费一区 | 免费成人午夜视频 | 亚洲精品国产电影 | 一区二区三区高清在线 | 91插视频| 国产成在线观看免费视频 | 国产精品高清在线观看 | 欧美不卡视频 | 激情.com| 欧美一区二区在线播放 | 久久美女精品国产精品亚洲 | 国产精品亚洲综合第一区 | 国产精品国产a级 | 91青青草视频在线观看 | 久久久久国产一区二区三区 | 午夜视频网 | 国产免费观看视频 | 中文字幕综合在线观看 | 久久亚洲精品中文字幕 | 欧美国产日韩在线观看 | 91青青操| 日韩欧美在线视频不卡免费视频 | 免费大片在线观看网站 | av免费在线观看网站 | 国产午夜精品一区二区三区嫩草 | 91精品久久 | 色综合久久88色综合天天 | 四虎tv在线观看884aa | 天天天天天天天操 |